ABCL
NASDAQAbCellera Biologics Inc.
News · 26 weeks54+91%
2026-03-012026-08-23
Mix4290d
- Insider13(31%)
- SEC Filings12(29%)
- Other8(19%)
- Earnings5(12%)
- Leadership2(5%)
- Offering2(5%)
Latest news
25 items- INSIDERDirector Hayden Michael R bought $570,442 worth of shares (53,613 units at $10.64) (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- PRMost AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that look different are treated as unrelated. That assumption is convenient, and it is often wrong, because biology repeatedly reaches the same function through completely different-looking structures. A c
- INSIDERDirector Montalbano John S. bought $110,300 worth of shares (10,000 units at $11.03), increasing direct ownership by 4% to 251,000 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERChief Financial Officer Booth Andrew bought $383,904 worth of shares (37,200 units at $10.32), increasing direct ownership by 8% to 482,800 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERDirector Hayden Michael R bought $481,033 worth of shares (46,387 units at $10.37) (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECSEC Form 8-K filed by AbCellera Biologics Inc.8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- SECSEC Form 424B5 filed by AbCellera Biologics Inc.424B5 - AbCellera Biologics Inc. (0001703057) (Filer)
- INSIDERDirector Hayden Michael R gifted 50,000 shares (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- PRAbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded WarrantsAbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares at a price to the public of $9.74999 per pre-funded warrant, which represents the per share public offering price of each common share less the $0.00001 per share exercise price for each pre-funded warrant. The gross proceeds to AbCellera from the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and e
- SECSEC Form 424B5 filed by AbCellera Biologics Inc.424B5 - AbCellera Biologics Inc. (0001703057) (Filer)
- PRThese Have the Market Hot Zone Catalysts and SetupsDENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Planet Green Holdings (NYSEAMERICAN:PLAG), NeOnc Technologies (NASDAQ:NTHI), and Quantum Corporation (NASDAQ:QMCO) made nice runs since our midday coverage. While AbCellera Biologics (NASDAQ:ABCL) and Bank of America are among the notable names reaching new 52-week highs Tuesday. However, among the group, NeOnc may be heading into Wednesday with the most clearly defined and potentially binary catalyst: topline Phase 2a data for its brain-cancer program. NeOnc: Wednesday’s Brain-Cancer Data Could be the Biggest Catalyst of the Group NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with a clinical catalyst that could sharply alter the ma
- PRAbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsAbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and pre-funded warrants are being offered by AbCellera. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. AbCellera intends to use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipelin
- PRThe Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major MilestonesDENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) — Today's market is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT) emerging as one of the session's standout movers while biotech names AbCellera Biologics (NASDAQ:ABCL), Silence Therapeutics (NASDAQ:SLN) and NeOnc Technologies (NASDAQ:NTHI) command attention around major clinical milestones. Socket Mobile: The Breakout Stock with a New Distribution Engine Socket Mobile (NASDAQ:SCKT) is kicking off the week as one of the market's most explosive small-cap movers after announcing a strategic partnership with 3Eye Technologies, a value-added dist
- PRAI Found an Influenza Target That Survives Viral MutationAUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. MindWalk Holdings Corp. (NASDAQ:HYFT) has built its entire technology stack around that gap, and in late July it put the result on a stage in front of the AI infrastructure industry. Three Layers, One Idea MindWalk describes itself as a Bio-Native AI c
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability ProfilePhase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose ABCL635 significantly improved sleep and patient global impression of change ABCL635 demonstrated a favorable tolerability profile AbCellera to host a conference call and live webcast today at 4:30 a.m. PT / 7:30 a.m. ET AbCellera (NASDAQ:ABCL) today announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. ABCL635 is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomoto
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET AbCellera (NASDAQ:ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day. A live audio webcast of the investor conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About ABCL635 ABCL635 is a potential first-in-class anti
- SECSEC Form 10-Q filed by AbCellera Biologics Inc.10-Q - AbCellera Biologics Inc. (0001703057) (Filer)
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Reports Q2 2026 Business ResultsAbCellera (NASDAQ:ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Since our last business update we signed two new collaborations, one with Jazz and one with Vertex, that leverage our T-cell engager platform to advance programs into the clinic and are adding over $100 million in upfront cash to our balance sheet." Q2 2026 Business Summary and Program Updates ABCL635 top-line data
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other ConditionsAbCellera (NASDAQ:ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. "We are excited to collaborate with Vertex, a recognized leader in innovation, to accelerate the development of new, transformative therapies," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We continue to see our TCE platform as a source for advancing impactful programs into the clinic, both internally and through strategic partnerships." "Vertex is committed to transforming the treatment landscape for people with serious diseases," s
- PRAn AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the NumbersIssued on behalf of MindWalk Holdings Corp. (NASDAQ:HYFT)USA News Group News CommentaryNEW YORK, July 23, 2026 /CNW/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can talk about accelerating the search for new medicines; far fewer can point to real revenue, real clients, and a business model that compounds. One small-cap AI biotech just put a set of numbers behind its version of that story, and they show a company whose pivot is starting to appear in its financials rather than only in its slide decks. The company reported full-year resu
- PRAs AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H
ABCL FAQ
7 questionsWhat does AbCellera Biologics Inc. do?
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.Where does ABCL stock trade?
AbCellera Biologics Inc. (ABCL) is listed on NASDAQ.What sector and industry is ABCL in?
AbCellera Biologics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbCellera Biologics Inc. go public?
AbCellera Biologics Inc. (ABCL) completed its IPO in 2020.What are analysts saying about ABCL?
AbCellera Biologics Inc. has had 8 recent analyst actions on file. The most recent action was from The Benchmark Company: Buy with a $1100.00 price target on 2026-07-07. Recent price targets range from $400.00 to $1100.00.What companies are similar to ABCL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ABCL side-by-side with any of them on Quantisnow.How can I track ABCL on Quantisnow?
Quantisnow aggregates AbCellera Biologics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABCL to receive live email and push alerts on every new disclosure.